Tests a brain stimulation device for nerve pain in neuromyelitis optica
Tests 10Hz brain stimulation in adults with neuromyelitis optica and neuropathic pain.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Key facts
- Where
- Xi'an, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07377305, who can take part
Where in China
- Tangdu HospitalXi'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tang-Du Hospital
- Trial code
- NCT07377305
- Record updated
- 29 January 2026
- Original description
This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD) complicated by neuropathic pain in China.Read full original descriptionShow less
A Single-center, Prospective, Single-arm Clinical Study: Evaluation of the Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD) complicated by neuropathic pain in China.
Inclusion: Patients diagnosed with NMOSD in accordance with the criteria of the International Panel for Neuromyelitis Optica Diagnosis (IPND); Patients were complicated with neuropathic pain, with a DN4 score ≥ 4; NRS score for pain ≥ 4 points, and neuropathic pain has persisted for more than 3 months; Patients receiving biological therapy and/or prednisone at a stable dose, with no adjustment of the treatment plan within 30 days before enrollment; Patients who have not adjusted any combination of standard analgesic drugs (including antiepileptic drugs, antidepressants, and opioid drugs) within 30 days before enrollment; Patients or their family members who have signed a written informed consent form.
Exclusion: Subjects who have used investigational drugs for pain control within 30 days before enrollment; Subjects with a concurrent diagnosis of peripheral neuropathy; Subjects with concurrent active central nervous system diseases; Subjects with a history of transcutaneous electrical nerve stimulation (TENS) allergy, latex allergy, or previous intolerance; Subjects with cognitive or mental disorders; Subjects with severe diseases related to the heart, liver, kidneys, or hematopoietic system; Subjects with implanted devices in the body (such as cardiac pacemakers, nerve stimulators, etc.); Other medical conditions or situations that the researcher deems may affect the achievement of the study objectives; Subjects participating in other clinical studies; Subjects who are pregnant, lactating, or planning to become pregnant during the study period; Subjects with contraindications to MRI examination; Subjects with head skin lesions.